Clin2Atlas
AtlasMental health & substance useDrug use disorders

Opioid use disorders

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251993 — Levomethadyl acetate approved (FDA)2008 — Methylnaltrexone approved (FDA)2014 — Naloxegol approved (FDA)
1993: Drug approval — Levomethadyl acetate approved (FDA). 2008: Drug approval — Methylnaltrexone approved (FDA). 2014: Drug approval — Naloxegol approved (FDA)

What's being tested now

2005: 1 trials started2006: 1 trials started2010: 1 trials started2017: 3 trials started2018: 3 trials started2019: 10 trials started2020: 10 trials started2021: 20 trials started2022: 12 trials started2023: 31 trials started2024: 65 trials started2025: 86 trials started2026: 98 trials started20102020202698

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 297 active Opioid Abuse trials on Clin2 →

Related

Cocaine use disordersAmphetamine use disordersCannabis use disordersOther drug use disorders

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.